Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANSOLYSEN vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Severe hypertension,Hypertensive crisis
Hypertension
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hepatic metabolism; excreted primarily unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 30-40% bound to serum albumin; binding is reversible and concentration-independent.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Vd is 0.5-1.0 L/kg indicating extensive tissue distribution (primarily in highly perfused organs), with little accumulation in fat.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is low (10-25%) due to significant first-pass metabolism; subcutaneous bioavailability >90%; intramuscular near 90%; intravenous 100%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in severe renal impairment. For GFR 10-50 m L/min: reduce dose by 50% and increase dosing interval. For GFR <10 m L/min: avoid use.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased toxicity.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not established; safety and efficacy in children have not been determined.
Not established; avoid use in children.
Use with caution; start at lower end of dosing range due to increased sensitivity and risk of hypotension and falls.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None specified in standard references.
None
Severe hypotension,Paralytic ileus,Bladder atony,Pupillary dilatation and photophobia,Loss of accommodation,Syncope and precipitating angina,Interstitial pulmonary edema and fibrosis
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to pentolinium,Uncooperative patients,Coronary insufficiency,Recent myocardial infarction,Severe renal impairment,Pyloric stenosis,Glaucoma,Bladder neck obstruction,Prostatic hypertrophy
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) as ganglionic blockers may potentiate pressor responses. Limit salt intake to manage blood pressure. Grapefruit juice may alter drug metabolism? No known significant interaction; however, general caution with high-tyramine foods is advised.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory depression due to ganglionic blockade. May cause neonatal hypotension if used near term.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excretion in human milk unknown; M/P ratio not available. Due to potential for adverse effects in nursing infants (e.g., hypotension, gastrointestinal disturbances), caution advised; consider alternative therapy.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No specific dosing guidelines; monitor maternal response carefully. Increased volume of distribution may require higher doses, but increased sensitivity may necessitate dose reduction. Use lowest effective dose.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
ANSOLYSEN (mecamylamine) is a secondary amine and a ganglionic blocker used in severe hypertension. Due to its narrow therapeutic index and risk of paralytic ileus, it is rarely used today. Monitor for orthostatic hypotension, urinary retention, and constipation. Avoid in patients with pyloric stenosis, recent myocardial infarction, or glaucoma. Use with caution in renal impairment as drug is renally excreted.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not double doses if missed.,Rise slowly from lying or sitting to prevent dizziness.,Avoid alcohol and hot baths/saunas as they may worsen hypotension.,Report severe constipation, difficulty urinating, or blurred vision immediately.,Do not discontinue abruptly; taper under medical supervision.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANSOLYSEN vs ALDORIL 25, answered by our medical review team.
ANSOLYSEN is a Antihypertensive that works by Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANSOLYSEN and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANSOLYSEN is: Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANSOLYSEN and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANSOLYSEN is classified as Category C. First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.